or Try an Advanced Search...

    Technical Analysis for CLYM - Climb Bio, Inc.

    Grade Last Price % Change Price Change
    F 3.82 -0.13% -0.01
    CLYM closed down 0.13 percent on Friday, November 1, 2024, on 39 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical CLYM trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Lower Bollinger Band Walk Weakness -0.13%
    Wide Bands Range Expansion -0.13%
    Gapped Up Strength -0.13%
    Down 3 Days in a Row Weakness -0.13%
    Down 4 Days in a Row Weakness -0.13%
    Older End-of-Day Signals for CLYM ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 23 hours ago
    Up 3% 1 day ago
    Fell Below Previous Day's Low 1 day ago
    Up 2% 1 day ago
    Up 1% 1 day ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    CLYM Chart by TradingView
    Basic chart:

    Profile

    Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wilmington, DE.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Molecular Biology Gene Therapy Immune Mediated Diseases Bioethics

    Is CLYM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 11 Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
    Oct 2 Eliem Therapeutics Changes Name to Climb Bio
    Oct 2 Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
    Sep 28 Private equity firms who have a significant stake must be disappointed along with institutions after Eliem Therapeutics, Inc.'s (NASDAQ:ELYM) market cap dropped by US$231m
    Sep 23 Eliem Therapeutics: Recent Strategic Pipeline Restructuring
    Aug 14 Eliem Therapeutics GAAP EPS of -$1.81
    Aug 14 Eliem Therapeutics Reports Second Quarter Financial Results
    Jul 24 Insider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells Shares
    Jul 22 IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
    Jul 19 Insider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ...
    See more CLYM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.55
    52 Week Low 2.35
    Average Volume 606,860
    200-Day Moving Average 5.57
    50-Day Moving Average 5.96
    20-Day Moving Average 4.73
    10-Day Moving Average 4.29
    Average True Range 0.36
    RSI (14) 23.08
    ADX 39.27
    +DI 9.51
    -DI 33.40
    Chandelier Exit (Long, 3 ATRs) 4.39
    Chandelier Exit (Short, 3 ATRs) 4.86
    Upper Bollinger Bands 5.78
    Lower Bollinger Band 3.67
    Percent B (%b) 0.07
    BandWidth 44.69
    MACD Line -0.59
    MACD Signal Line -0.55
    MACD Histogram -0.042
    Fundamentals Value
    Market Cap 105.33 Million
    Num Shares 27.6 Million
    EPS -1.46
    Price-to-Earnings (P/E) Ratio -2.62
    Price-to-Sales 0.00
    Price-to-Book 0.66
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.13
    Resistance 3 (R3) 4.15 4.06 4.08
    Resistance 2 (R2) 4.06 3.99 4.05 4.06
    Resistance 1 (R1) 3.94 3.94 3.90 3.92 4.04
    Pivot Point 3.86 3.86 3.84 3.85 3.86
    Support 1 (S1) 3.74 3.78 3.70 3.72 3.60
    Support 2 (S2) 3.65 3.73 3.64 3.58
    Support 3 (S3) 3.53 3.65 3.56
    Support 4 (S4) 3.51